|
1
|
Bareschino MA, Schettino C, Rossi A, et
al: Treatment of advanced non small cell lung cancer. J Thorac Dis.
3:122–133. 2011.PubMed/NCBI
|
|
2
|
Crinò L, Dansin E, Garrido P, et al:
Safety and efficacy of first-line bevacizumab-based therapy in
advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a
phase 4 study. Lancet Oncol. 11:733–740. 2010.PubMed/NCBI
|
|
3
|
Sandler A, Gray R, Perry MC, et al:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sandler A, Yi J, Dahlberg S, et al:
Treatment outcomes by tumor histology in Eastern Cooperative Group
Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced
non-small cell lung cancer. J Thorac Oncol. 5:1416–1423. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reck M, von Pawel J, Zatloukal P, et al:
Phase III trial of cisplatin plus gemcitabine with either placebo
or bevacizumab as first-line therapy for nonsquamous non-small-cell
lung cancer: AVAil. J Clin Oncol. 27:1227–1234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reck M, von Pawel J, Zatloukal P, et al;
BO17704 Study Group. Overall survival with cisplatin-gemcitabine
and bevacizumab or placebo as first-line therapy for nonsquamous
non-small-cell lung cancer: results from a randomised phase III
trial (AVAiL). Ann Oncol. 21:1804–1809. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yuan F, Chen Y, Dellian M, et al:
Time-dependent vascular regression and permeability changes in
established human tumor xenografts induced by an anti-vascular
endothelial growth factor/vascular permeability factor antibody.
Proc Natl Acad Sci USA. 93:14765–14770. 1996. View Article : Google Scholar
|
|
8
|
Mancuso MR, Davis R, Norberg SM, et al:
Rapid vascular regrowth in tumors after reversal of VEGF
inhibition. J Clin Invest. 116:2610–2621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bagri A, Berry L, Gunter B, et al: Effects
of anti-VEGF treatment duration on tumor growth, tumor regrowth,
and treatment efficacy. Clin Cancer Res. 16:3887–3900. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ebos JM, Lee CR, Cruz-Munoz W, et al:
Accelerated metastasis after short-term treatment with a potent
inhibitor of tumor angiogenesis. Cancer Cell. 15:232–239. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nadler E, Yu E, Ravelo A, Sing A, Forsyth
M and Gruschkus S: Bevacizumab treatment to progression after
chemotherapy: outcomes from a U.S. community practice network.
Oncologist. 16:486–496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kelly K, Crowley J, Bunn PA Jr, et al:
Randomized phase III trial of paclitaxel plus carboplatin versus
vinorelbine plus cisplatin in the treatment of patients with
advanced non - small-cell lung cancer: a Southwest Oncology Group
trial. J Clin Oncol. 19:3210–3218. 2001.PubMed/NCBI
|
|
13
|
Scagliotti GV, De Marinis F, Rinaldi M, et
al; Italian Lung Cancer Project. Phase III randomized trial
comparing three platinum-based doublets in advanced non-small-cell
lung cancer. J Clin Oncol. 20:4285–4291. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schiller JH, Harrington D, Belani CP, et
al; Eastern Cooperative Oncology Group. Comparison of four
chemotherapy regimens for advanced non-small-cell lung cancer. N
Engl J Med. 346:92–98. 2002. View Article : Google Scholar
|
|
15
|
Fossella F, Pereira JR, von Pawel J, et
al: Randomized, multinational, phase III study of docetaxel plus
platinum combinations versus vinorelbine plus cisplatin for
advanced non-small-cell lung cancer: the TAX 326 study group. J
Clin Oncol. 21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gridelli C, Ardizzoni A, Douillard JY, et
al: Recent issues in first-line treatment of advanced
non-small-cell lung cancer: Results of an International Expert
Panel Meeting of the Italian Association of Thoracic Oncology. Lung
Cancer. 68:319–331. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Scagliotti GV, Parikh P, von Pawel J, et
al: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small-cell lung cancer. J Clin Oncol.
26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
